Hepamerz%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252528l-Ornithine%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520l-Aspartate%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520-%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520lola%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252529

## Hepamerz (l-Ornithine l-Aspartate) ### Overview Hepamerz is a combination of two amino acids, L-ornithine and L-aspartate. It is believed to work by promoting ammonia detoxification in the liver and brain. ### Primary Indications * Treatment of latent and manifest hepatic encephalopathy (HE) in patients with hyperammonemia associated with liver disease. ### Adult Dosing * **Oral:** Typically, 3-6 grams (e.g., one sachet of 3g or two sachets of 3g) two to three times daily. The total daily dose can range from 9 to 18 grams. * **Intravenous (IV):** Usually 5 grams (one ampoule) or 10 grams (two ampoules) once or twice daily, administered as an infusion over 30-60 minutes. Dosing depends on the severity of hepatic encephalopathy and the degree of hyperammonemia. Local protocols may guide specific dosing strategies. ### Pediatric Dosing * Information on pediatric dosing is limited and not well-established. Use with caution and under expert guidance. ### Dose Adjustments * No specific dose adjustments are typically required for renal or hepatic impairment, as the drug is primarily metabolized in the liver. However, caution is advised in severe liver disease. ### Contraindications * Severe renal insufficiency (creatinine > 3 mg/dL). * Known hypersensitivity to L-ornithine or L-aspartate. * Rare metabolic disorders like Ornithine Transcarbamylase deficiency (unless diagnosed and managed appropriately). ### Adverse Effects * Gastrointestinal disturbances: Nausea, vomiting, abdominal pain, diarrhea. * Rarely: Allergic reactions, rash, itching. ### Key Drug Interactions * No significant drug interactions are well-documented. ### Monitoring * Serum ammonia levels. * Neurological status and assessment for signs of hepatic encephalopathy. * Renal function (especially in patients with pre-existing kidney issues). ### Clinical Pearls * L-ornithine l-aspartate is used to reduce elevated ammonia levels in patients with liver disease, potentially improving neurological function. * Oral administration is typically used for milder cases or as maintenance therapy, while IV administration is often used for more acute or severe presentations. * Ensure adequate hydration, especially when administering intravenously. *** **Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for complete details and to verify dosage and safety information before patient administration.